UTHR - CIK 0001082554
The table below shows UNITED THERAPEUTICS Corp's cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | $463.30M | $461.20M | $376.50M | $374.80M | $288.70M | $89.80M |
| Capital expenditure | $100.80M | $74.90M | $38.20M | $41.30M | $13.50M | $10.60M |
| Investing cash flow | $743.70M | -$164.70M | $735.30M | -$221.10M | -$359.20M | -$6.30M |
| Dividends paid | - | - | - | - | - |
UNITED THERAPEUTICS Corp reported operating cash flow of $1.56B for fiscal year 2025. That is up 17.6% from $1.33B in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from $643.60M (FY 2016) to $1.56B. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | $1.50B | $0.00 | $1.00B | $0.00 | - | - |
| Financing cash flow | -$1.48B | -$93.80M | -$1.07B | $48.60M | -$11.00M | $10.10M |